The German Cancer Congress 2026 (DKK) is taking place from February 18th to 21st, 2026, in Berlin and is considered one of the most important oncology conferences in the German-speaking world.
It provides a central platform for interdisciplinary exchange on current developments in cancer medicine, innovative therapeutic strategies, and new scientific findings.
This year, GBG is present with three scientific posters, presenting current results from its study activities.
Below you will find an overview as well as further information on the presented posters.
Congress Contributions
🔬 Molecular testing in breast cancer: The key to more personalized and effective therapies
The data show: 63.8% of the samples analyzed exhibited pathogenic variants; in 50%, directly actionable alterations were found (including BRCA1/2, PIK3CA, ESR1, ERBB2, PALB2).
Conclusion: Molecular testing should be performed before the start of first-line therapy in order to use PI3K or PARP inhibitors in a targeted manner and to plan further treatment options at an early stage.
🧪 Randomized phase II, open-label, multicenter study evaluating the addition of elacestrant to olaparib compared to olaparib monotherapy in patients with HR+/HER2- locally advanced or metastatic breast cancer with germline BRCA1/2 mutations – ELEMENT (Trial in Progress)
A randomized phase II study is investigating the combination of elacestrant and olaparib in HR+/HER2− metastatic breast cancer with gBRCA1/2 mutation—aiming to further improve the efficacy of PARP inhibition.
🧠 HER2 IHC status of primary breast cancer tumor and brain metastases in the BMBC registry
The analysis shows: The HER2 IHC status of brain metastases is significantly associated with overall survival and may serve as a prognostic biomarker.
In addition, HER2-ultralow, HER2-low, or HER2 3+ constellations were frequently observed—with potential relevance for modern HER2-targeted antibody-drug conjugates.
